Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov 17;18(11):2435.
doi: 10.3390/ijms18112435.

Role of Transforming Growth Factor β in Uterine Fibroid Biology

Affiliations
Review

Role of Transforming Growth Factor β in Uterine Fibroid Biology

Michał Ciebiera et al. Int J Mol Sci. .

Abstract

Uterine fibroids (UFs) are benign tumors of the female genital tract made of the smooth muscle of the uterus. UF growth depends mostly on the influence of the steroid hormones and selected growth factors. Transforming growth factor β (TGF-βs) is a polypeptide that consists of three isoforms: TGF-β1, TGF-β2, and TGF-β3. At present, TGF-β is considered to be one of the key factors in the pathophysiology of UFs. It plays a major role in cellular migration within the tumor, stimulates tumor growth, and enhances tumor metabolism. As a consequence of various dependencies, the synthesis and release of TGF-β in a UF tumor is increased, which results in excessive extracellular matrix production and storage. High concentrations or overexpression of TGF-β mediators may be responsible for clinically symptomatic UFs. The aim of this review was to check the available evidence for the influence of the TGF-β family on UF biology. We conducted their search in PubMed of the National Library of Medicine with the use of the following selected keywords: "uterine fibroid", "leiomyoma", and "transforming growth factor β". After reviewing the titles and abstracts, more than 115 full articles were evaluated. We focused on the TGF-β-related molecular aspects and their influence on the most common symptoms that are associated with UFs. Also, we described how the available data might implicate the current medical management of UFs.

Keywords: leiomyoma; pathophysiology; therapy; transforming growth factor β; uterine fibroid.

PubMed Disclaimer

Conflict of interest statement

Michał Ciebiera, Aneta Słabuszewska-Jóźwiak, Grzegorz Jakiel have received personal fees from Gedeon Richter not related to this work. The Gedeon Richter had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

Figures

Figure 1
Figure 1
TGF-β isoforms, TGF-β receptors; TGF-β intracellular signaling pathways. TGF-β: transforming growth factor β; FAK: focal adhesion kinase; TAK: TGF-β-activated kinase; MKK: Mitogen-activated protein kinase kinase; JNK: c-Jun N-terminal kinase; p38: p38 mitogen-activated protein kinases; PI3K: Phosphoinositide 3-kinase; Akt: Protein kinase B; mTOR: mechanistic target of rapamycin; Ras: Ras protein; Raf: Raf protein; MEK: MAPK/ERK kinase; ERK: Extracellular signal-regulated kinases; Smad: Smad protein.
Figure 2
Figure 2
Increased secretion of Wnt ligands under the influence of estrogen and progesterone (Figure 3) from smooth muscle cells, which are placed around uterine fibroid stem cells. This pathway leads to excessive production of the transforming growth factor β and extracellular matrix, as well asenhanced proliferation of uterine fibroid stem cells.
Figure 3
Figure 3
Estrogen and progesterone—two main hormones influencing the metabolism and proliferation of uterine smooth muscle cells or uterine fibroid cells. Wnt signaling is one of the most important pathways in uterine fibroid pathophysiology. Excessive production of transforming growth factor β depends greatly on Wnt signals. The drugs influencing the hormonal pathways and their potential site of effect are presented. ER: Estrogen receptor; PR: Progesterone receptor.

Similar articles

Cited by

References

    1. Parker W.H. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil. Steril. 2007;87:725–736. doi: 10.1016/j.fertnstert.2007.01.093. - DOI - PubMed
    1. Stewart E.A., Laughlin-Tommaso S.K., Catherino W.H., Lalitkumar S., Gupta D., Vollenhoven B. Uterine fibroids. Nat. Rev. Dis. Prim. 2016;2:16043. doi: 10.1038/nrdp.2016.43. - DOI - PubMed
    1. Soliman A.M., Margolis M.K., Castelli-Haley J., Fuldeore M.J., Owens C.D., Coyne K.S. Impact of uterine fibroid symptoms on health-related quality of life of us women: Evidence from a cross-sectional survey. Curr. Med. Res. Opin. 2017;33:1971–1978. doi: 10.1080/03007995.2017.1372107. - DOI - PubMed
    1. Stewart E.A. Clinical practice. Uterine fibroids. N. Engl. J. Med. 2015;372:1646–1655. doi: 10.1056/NEJMcp1411029. - DOI - PubMed
    1. Metwally M., Farquhar C.M., Li T.C. Is another meta-analysis on the effects of intramural fibroids on reproductive outcomes needed? Reprod. Biomed. Online. 2011;23:2–14. doi: 10.1016/j.rbmo.2010.08.006. - DOI - PubMed

MeSH terms